Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
:ZBIO
RESEARCH TOOLSreports
ZBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.83 - $26.25
Previous CloseN/A
Volume96.53K
Average Volume (3M)174.97K
Market Cap
$322.21M
Enterprise Value$320.52M
Total Cash (Recent Filing)$67.21M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta-0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding41,791,040
10 Day Avg. Volume259,220
30 Day Avg. Volume174,968
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit64.10
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$29.75Price Target Upside285.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initial wAIHA data strengthen the proof-of-concept for obexelimab, with more than 60% of patients achieving a hemoglobin increase and no major safety events reported.
Product DifferentiationObexelimab is specifically designed to inhibit cellular activity associated with autoimmune diseases and do so without associated B cell depletion.
Bears Say
Investor ConcernsZBIO shares have faced pressure due to investor concerns on competition for obexelimab in IgG4-RD and the lack of near-term data catalysts.
Stock PerformanceStock performance has been underwhelming since IPO, which is a disconnect from the fundamental value.
---
Ownership Overview
40.40% Insiders
6.67% Mutual Funds
44.77% Other Institutional Investors
6.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $5.83 and its highest was $26.25 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $322.21M.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Nov 12, 2024. The company reported -$5.02 earnings per share for the quarter, missing the consensus estimate of -$0.951 by -$4.069.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 41,791,040 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$5.02 in its last earnings report, missing expectations of -$0.951. Following the earnings report the stock price went down -3.103%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
---
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.75 (285.86% Upside)
$29.75 (285.86% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 437.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $77.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
---
ZBIO Stock 12 Month Forecast
Average Price Target
$29.75
▲(285.86% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering ZBIO
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-9.00%
reiterated a buy rating 26 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.00% per trade.
---